Adamas Pharmaceuticals, Inc.   Report issue

For profit Phase 2 Phase 4
Founded: Emeryville CA United States (2000)
Status: Acquired by Supernus Pharmaceuticals (2021)

Organization Overview

First Clinical Trial
2009
NCT00979251
First Marketed Drug
2017
amantadine (symmetrel)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ADAMAS PHARMA | Adamas Pharmaceuticals | Adamas Pharmaceuticals, Inc.